Coordinated upregulation of COX-2 and NF-κB is a steady feature of laryngeal carcinogenesis

ORL

Volumn 69, Issue 3, 2007, Pages 181-189

  Kourelis, Konstantinos ^a,b,e   Sotiropoulou Bonikou, Georgia ^a   Vandoros, Gerasimos ^c   Repanti, Maria ^d   Varakis, Ioannis ^a   Goumas, Panagiotis ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c General Hospital of Aegion   (Greece)

^d Department of Pathology   (Greece)

^e NONE   (Greece)

Author keywords

Carcinogenesis; Larynx

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARAFFIN; PROTEIN SUBUNIT; SYNAPTOTAGMIN I;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CYTOPLASM; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; PRECANCEROUS CONDITIONS; UP-REGULATION;

EID: 34247129682     PISSN: 03011569     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099229     Document Type: Article

References (45)

1. Weisman R, Kris S, Orloff L: Neoplasms of the larynx and laryngopharynx; in Snow J, Ballenger J (eds): Ballenger's Otorhinolaryngology Head and Neck Surgery, ed 16. Hamilton, BC Decker, 2003, pp 1255-1297.
2. Kim ES, Hong WK, Khuri FR: Chemoprevention of aerodigestive tract cancers. Annu Rev Med 2002;53:223-243.
3. Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med 2001;345:1890-1900.
4. Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-968.
5. Tanabe T, Tohnai N: Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002;68-69:95-114.
6. Subbaramaiah K, Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
7. Fitzpatrick FA: Inflammation, carcinogenesis and cancer. Int Immunopharmacol 2001;1:1651-1667.
8. Wiese FW, Thompson PA, Kadlubar FF: Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 2001;22:5-10.
9. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
10. Mohan S, Epstein JB: Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 2003;39:537-546.
11. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999;90:1152-1162.
12. Celec P: Nuclear factor kappa B - molecular biomedicine: the next generation. Biomed Pharmacother 2004;58:365-371.
13. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
14. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-663.
15. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T: Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995;270:24965-24971.
16. Beg AA, Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996;274:782-784.
17. Biswas DK, Cruz AP, Gansberger E, Pardee AB: Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000;97:8542-8547.
18. Levine L, Lucci JA 3rd, Pazdrak B, Cheng JZ, Guo YS, Townsend CM Jr, Hellmich MR: Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003;63:3495-3502.
19. Bharti AC, Aggarwal BB: Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-888.
20. Schottenfeld D, Beebe-Dimmer J: Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56:69-83.
21. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-2492.
22. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994.
23. Nathan CA, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, Glass J: COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001;92:1888-1895.
24. Renkonen J, Wolff H, Paavonen T: Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 2002;440:594-597.
25. Mobius C, Stein HJ, Spiess C, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR: COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol 2005;31:755-759.
26. Heppner GH: Tumor heterogeneity. Cancer Res 1984;44:2259-2265.
27. Nakayama H, Ikebe T, Beppu M, Shirasuna K: High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 2001;92:3037-3044.
28. Ahn KS, Aggarwal BB: Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann NY Acad Sci 2005;1056:218-233.
29. Lehmann W, Raymond L, Faggiano F, Sancho-Garnier H, Blanchet F, Del Moral A, Zubiri L, Terracini B, Berrino F, Pequignot G, et al: Cancer of the endolarynx, epilarynx and hypopharynx in south-western Europe: assessment of tumoral origin and risk factors. Adv Otorhinolaryngol 1991;46:145-156.
30. Rayet B, Gelinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-6947.
31. Tamatani T, Azuma M, Aota K, Yamashita T, Bando T, Sato M: Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells. Cancer Lett 2001;171:165-172.
32. Patel A, Miller L, Ahmed K, Ondrey F: NF-kappa-B downregulation strategies in head and neck cancer treatment. Otolaryngol Head Neck Surg 2004;131:288-295.
33. Farina AR, Tacconelli A, Vacca A, Maroder M, Gulino A, Mackay AR: Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-NSH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ 1999;10:353-367.
34. Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H: NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631-21638.
35. Yang GZ, Li L, Ding HY, Zhou JS: Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: an immunohistochemical study. Exp Mol Pathol 2005;79:214-218.
36. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Muhldorfer S: Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci 2004;49:1075-1083.
37. Nadjar A, Tridon V, May MJ, Ghosh S, Dantzer R, Amedee T, Parnet P: NFkappaB activates in vivo the synthesis of inducible Cox-2 in the brain. J Cereb Blood Flow Metab 2005;25:1047-1059.
38. Cherukuri DP, Goulet AC, Inoue H, Nelson MA: Selenomethionine regulates cyclooxygenase-2 (COX-2) expression through nuclear factor-kappa B (NF-kappaB) in colon cancer cells. Cancer Biol Ther 2005;4:175-180.
39. Tian B, Brasier AR: Identification of a nuclear factor kappa B-dependent gene network. Recent Prog Horm Res 2003;58:95-130.
40. Schooley K, Zhu P, Dower SK, Qwarnstrom EE: Regulation of nuclear translocation of nuclear factor-kappaB relA: evidence for complex dynamics at the single-cell level. Biochem J 2003;369:331-339.
41. Ghiorzo P, Mantelli M, Gargiulo S, Gramigni C, Pastorino L, Banelli B, Villaggio B, Coccia MC, Sementa AR, Garre C, Bianchi-Scarra G: Inverse correlation between p16INK4A expression and NF-kappaB activation in melanoma progression. Hum Pathol 2004;35:1029-1037.
42. Poligone B, Baldwin AS: Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem 2001;276:38658-38664.
43. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
44. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R: Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005;104:879-890.
45. Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N: Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005;11:6738-6744.